Whole body KO mice |
Cflip−/− |
Embryonic lethality |
[82] |
Cflip-l+46 mutant |
Embryonic lethality |
[83] |
Cflip−/−Ripk3−/− |
Embryonic lethality |
[84] |
Cflip−/−Fadd−/−Ripk3−/− |
Normal development |
[84] |
Conditional KO mice |
T cells |
Increased cell death |
[85,86,87,88] |
B cells |
Increased cell death |
[89,90] |
Myeloid lineage |
Growth retardation, Splenomegaly |
[91,92] |
Dendritic cells |
Increased inflammation |
[93,94] |
Liver |
Increased liver failure |
[95,96,97,98,99,100] |
Intestine |
Increased cell death and inflammation |
[95,101] |
Skin epidermis |
Increased cell death and inflammation |
[102,103] |
Transgenic mice |
cFLIPR in Cflip-deficient T cells |
Similar to Cflip-deficient T cells |
[104,105] |
cFLIPL in T cells |
Increased survival |
[106,107,108,109,110,111,112,113,114,115] |
cFLIPS in T cells |
Increased survival |
[116,117] |
cFLIPL in neuron |
Increased survival |
[118] |
cFLIPL in thyroid |
Better resolution from autoimmune disease |
[119,120,121,122] |
cFLIPL in heart |
Reduced cardiac hypertrophy, prevention of cardiac remodeling |
[123,124,125] |
cFLIPL in eosinophil |
Increased survival |
[126] |
|
cFLIPL in testis |
Testis atrophy |
[127] |
|
cFLIPL in muscle |
Muscle aging |
[128] |
|
cFLIPR in hematopoietic cells |
Better bacterial clearance, increased autoimmune disease |
[129,130] |